Inactive Instrument

OYSR POIN Stock

OYST

US69242L1061

Analysts' recommendations: OYSR POIN

22-11-08	Piper Sandler Downgrades Oyster Point Pharma to Neutral From Overweight, Adjusts Price Target to $11 From $15	MT
22-11-08	Chardan Downgrades Oyster Point Pharma to Neutral From Buy on Proposed Sale to Viatris, Trims Price Target to $13 From $22	MT
22-08-11	Chardan Research Starts Oyster Point Pharma at Buy With $22 Price Target	MT
22-07-18	HC Wainwright Initiates Oyster Point Pharma at Buy With $20 Price Target	MT
22-05-31	Piper Sandler Adjusts Price Target on Oyster Point Pharma to $15 From $60, Reiterates Overweight Rating	MT

More recommendations

News in other languages: OYSR POIN

21-10-18	MÄRKTE USA/Börse hakt schwache Daten ab - Technologiewerte gesucht
21-10-18	MÄRKTE USA/Erholt von Anfangsverlusten - Technologiewerte vorne
21-10-18	MÄRKTE USA/Wall Street von schwachen Daten belastet
21-10-18	MÄRKTE USA/Wall Street dürfte mit Abgaben in die Woche starten

More news

Managers and Directors: OYSR POIN

Manager	Title	Age	Since
Raegan McClain CMP	Compliance Officer	-	2021-11-23
George Donato COO	Chief Operating Officer	-	-
Marian Macsai CTO	Chief Tech/Sci/R&D Officer	-	2020-12-06

More insiders

Oyster Point Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ophthalmic diseases. The Company's lead product candidate is TYRVAYA Nasal Spray, a nicotinic acetylcholine receptor (nAChR) agonist for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray's is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the trigeminal parasympathetic pathway (TPP) and stimulating the glands and cells responsible for natural tear film production. It is sprayed into the anterior portion of the nasal cavity and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.

Employees

303

Sector

More about the company

23-01-03	Viatris Completes Acquisitions of Oyster Point Pharma, Famy Life Sciences	MT
23-01-03	Oyster Point Pharma, Inc. Announces Board Resignations	CI
23-01-03	Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from NASDAQ Composite Index	CI
23-01-03	Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from S&P TMI Index	CI
23-01-02	Viatris Inc. completed the acquisition of Oyster Point Pharma, Inc. from a group of shareholders.	CI
23-01-02	Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from S&P Global BMI Index	CI
22-12-16	Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from NASDAQ Biotechnology Index	CI
22-11-10	Oyster Point Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-11-10	Earnings Flash (OYST) OYSTER POINT PHARMA Reports Q3 Revenue $5.6M	MT
22-11-08	Piper Sandler Downgrades Oyster Point Pharma to Neutral From Overweight, Adjusts Price Target to $11 From $15	MT
22-11-08	Chardan Downgrades Oyster Point Pharma to Neutral From Buy on Proposed Sale to Viatris, Trims Price Target to $13 From $22	MT
22-11-07	Health Care Up Amid Deal Activity -- Health Care Roundup	DJ
22-11-07	Stocks Advance Ahead of Tuesday's Midterm Elections	MT

23-01-03	OYSTER POINT PHARMA, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
22-12-07	OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST	BU
22-12-05	Oyster Point Pharma Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635	AQ
22-12-02	Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
22-12-02	Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-01-02	Invus Financial Advisors LLC	Tender	Company	2,768,586	10.3135%
23-01-02	NEA Management Co. LLC	Tender	Company	5,925,287	22.0728%
23-01-02	Aimee Weisner	Issuer sale	Director	47,322	0.1763%

OYSR POIN Stock

Stocks

OYST

US69242L1061

Latest news : OYSR POIN

Analysts' recommendations: OYSR POIN

Press Releases: OYSR POIN

News in other languages: OYSR POIN

Quotes and Performance

Managers and Directors: OYSR POIN

Latest insider transactions

Company Profile